Analyst Price Targets — ATRC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 6, 2026 12:33 pm | — | Canaccord Genuity | $55.00 | $28.60 | TheFly | AtriCure price target raised to $55 from $53 at Canaccord |
| February 18, 2026 12:08 pm | — | UBS | $55.00 | $32.97 | TheFly | AtriCure price target lowered to $55 from $60 at UBS |
| February 18, 2026 12:02 pm | William Plovanic | Canaccord Genuity | $53.00 | $32.97 | TheFly | AtriCure price target lowered to $53 from $64 at Canaccord |
| February 18, 2026 11:09 am | — | Oppenheimer | $44.00 | $32.97 | TheFly | AtriCure downgraded to Perform from Outperform at Oppenheimer |
| October 30, 2025 10:27 am | William Plovanic | Canaccord Genuity | $64.00 | $35.44 | StreetInsider | AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity |
| July 30, 2025 11:07 am | — | BTIG | $54.00 | $35.13 | TheFly | AtriCure price target raised to $54 from $52 at BTIG |
| July 31, 2024 6:57 am | Rick Wise | Stifel Nicolaus | $26.00 | $22.00 | TheFly | AtriCure price target lowered to $26 from $30 at Stifel |
| July 31, 2024 6:51 am | Matt O'Brien | Piper Sandler | $40.00 | $22.00 | TheFly | AtriCure price target lowered to $40 from $65 at Piper Sandler |
| July 31, 2024 4:58 am | Marie Thibault | BTIG | $53.00 | $22.00 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG |
| May 2, 2024 5:54 am | Mike Matson | Needham | $40.00 | $24.76 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $40 at Needham |
Latest News for ATRC
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23,…
[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
AtriCure, Inc. (ATRC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.